06th week of 2009 patent applcation highlights part 39 |
Patent application number | Title | Published |
20090035266 | IMMUNOGENIC PEPTIDES AND METHODS OF USE - The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described. | 2009-02-05 |
20090035267 | ACYCLIC, PYRIDAZINONE-DERIVED HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention. | 2009-02-05 |
20090035268 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters or prodrugs thereof: | 2009-02-05 |
20090035269 | PARAPOXVIRUSES IN COMBINATION WITH CLASSICAL CYTOTOXIC CHEMOTHERAPEUTIC AGENTS AS BIOCHEMOTHERAPY FOR THE TREATMENT OF CANCER - The invention relates to a method for the production of a pharmaceutical composition for treating cancer by combining | 2009-02-05 |
20090035270 | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF alpha - The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and rumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone. | 2009-02-05 |
20090035271 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2009-02-05 |
20090035272 | Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors - The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention. | 2009-02-05 |
20090035273 | Combination treatment method with interferon-tau - A method of treating conditions responsive to therapy with interferon-alpha or interferon-beta is provided, where the dose of interferon-alpha or interferon-beta is reduced and a dose of interferon-tau is additionally administered. The method results in efficacious therapy with a reduction in unwanted adverse events. | 2009-02-05 |
20090035274 | TREATMENT AND/OR PREVENTION OF CANCER AND/OR ARTHRITIS - The invention relates to the use of INSP163 for treatment and/or prevention of cancer and/or musculoskeletal/connective tissue disorder, in particular of lung cancer and/or osteoarthritis. Combinations of INSP163 with an interferon, a TNF antagonist or a further anti-cancer or anti-arthritis agent are also within the present invention. | 2009-02-05 |
20090035275 | Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of NAD - Pharmaceutical and cosmetic formulations and methods for optimizing the intracellular concentrations of NAD are provided. The present methods and compounds relate to the use of PBEF, PRPP and various forms of nicotinamide, individually or in combination, for therapeutic, cyto-protective, cosmetic and anti-aging purposes. PBEF, PRPP and nicotinamide, individually or in combination, as administered according to the invention, increase the metabolic fitness, health and performance of the cell, and thereby increase the cell's level of health during its lifecycle. By way of the present formulations and methods, optimizing the intracellular concentration of NAD | 2009-02-05 |
20090035276 | USE OF A COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT - The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R. | 2009-02-05 |
20090035277 | Hepatitis C Virus Nucleic Acid Vaccine - The present invention features nucleic acid constructs that can be used as a HCV nucleic acid vaccine, vaccine component, or in the production of a HCV vaccine. Described constructs include those: (1) encoding for a chimeric HCV polypeptide containing a NS3-4A region based on a first HCV strain and an NS3-NS4A-NS4B-NS5A or an NS3-NS4A-NS4B-NS5A-NS5B region based on a second strain; and (2) a chimpanzee based adenovector encoding an HCV polypeptide. | 2009-02-05 |
20090035278 | REOVIRUSES HAVING MODIFIED SEQUENCES - The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses. | 2009-02-05 |
20090035279 | GENETIC VARIANTS ON CHR 15Q24 AS MARKERS FOR USE IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF EXFOLIATION SYNDROME AND GLAUCOMA - The present invention relates to methods of diagnosing a susceptibility to an ocular disorder, including glaucoma and exfoliation syndrome. The invention provides methods of diagnosing an increased or decreased susceptibility to exfoliation syndrome and glaucoma, and methods for risk assessment, treatment and prognosis. The invention further relates to kits for use in the methods of the invention. | 2009-02-05 |
20090035280 | AGROCHEMICALLY ACTIVE MICROBIAL FORMULATION - The present invention provides an agrochemically active microbial formulation comprising a combination of an agrochemically active microbe with a specified ester compound and a surfactant, the formulation exhibiting a stable pest controlling effect with no harmful effect on a plant and having highly stable viability of the agrochemically active microbe | 2009-02-05 |
20090035281 | COMBINATION OF INTERLEUKIN-6 ANTAGONISTS AND ANTIPROLIFERATIVE DRUGS - The combination of an interleukin-6 (IL-6) antagonist and an antiproliferative drug is described. In its preferred embodiment, the present invention describes the combination of an IL-6 superantagonist, particularly a superantagonist totally incapable of binding gp130 and an antiproliferative drug belonging to the glucocorticoid class (SANT-7 and dexamethasone). The combination according to the present invention has shown surprising synergism in an animal model of multiple myeloma and the ability to overcome the resistance to the antiproliferative drug developed by myeloid cells. The combination according to the present invention is useful for the preparation of a medicament for the treatment of tumours, particularly IL-6-dependent tumours. | 2009-02-05 |
20090035282 | Pluripotent embryonic-like stem cells derived from teeth and uses thereof - A stem cell which is obtainable from the non-embryonic tissue isolated from the dental follicle of tooth or wisdom tooth which are able to differentiate into a periodontal ligament like membrane structure. | 2009-02-05 |
20090035283 | Composition and Method for Inhibition of Melanin Synthesis - The present invention provides a whitening cosmetic composition comprising a stem cell, a culture medium thereof or a protein isolated from the culture medium and a method of whitening a skin which comprises administering to the skin an therapeutically effective amount of a stem cell, a culture medium thereof or a protein isolated from the culture medium. | 2009-02-05 |
20090035284 | DERIVATION OF NEURAL STEM CELLS FROM EMBRYONIC STEM CELLS AND METHODS OF USE THEREOF - Provided is a method for the derivation of neural stem cells (NSCs) from embryonic stem cells (ESCs) and the use of the NSCs for treatment of various neural disorders. The NSCs that are derived from the ESCs are tissue-specific multipotent NSCs with a stable growth rate, unlimited self-renewal capacity, and a predictable differentiation profile. Being both non-tumorigenic and engraftable, the NSCs of the present invention have utility in repopulation stroke-damaged tissue. The NSCs of the present invention may be differentiated to produce tyrosine-hydroxylase expressing neurons, which may be used as a source of dopaminergic neurons for subjects suffering from a condition characterized by dopaminergic dysfunction, such as Parkinson's disease. | 2009-02-05 |
20090035285 | Compositions and Methods for Enrichment of Neural Stem Cells Using Ceramide Analogs - The present invention provides compositions and methods for human neural cell production. More particularly, the present invention provides cellular differentiation methods employing amphiphilic lipid compounds, preferably ceramide analogs of the β-hydroxyalkylamine type and optionally employing an essentially serum free MEDII conditioned medium for the generation of human neural cells from pluripotent human cells. The methods alternatively comprise modulating apoptosis by modifying the levels of PAR-4, with or without the presence of amphiphilic lipid compounds and optionally employing MEDII conditioned medium. The methods alternatively encompass modulating apoptosis by modulating the intracellular concentration of endogenous lipid second messengers, such as ceramide. | 2009-02-05 |
20090035286 | Intracoronary, intracardiac, or intravenous infusion of a mixture of autologous bone marrow derived mononuclear cells and autologous bone marrow derived mesenchymal stem cells for utilization and rescue of infarcted myocardium - The present invention is a method for improving cardiac function and myocardial regeneration in living subjects after the occurrence of myocardial infarction. The method is a combination stem cell therapy involving a mixture of bone marrow-derived mesenchymal stem cells and bone marrow derived mononuclear cells surgically implanted by using either a direct or catheter-mediated injection into damaged myocardium. Studies have shown that the implant improves heart function and myocardial regeneration and echocardiographic measurements. | 2009-02-05 |
20090035287 | ATRIAL NATRIURETIC PEPTIDE (ANP) SPLICE VARIANTS AND METHODS OF USING SAME - Novel ANP polypeptides and polynucleotides encoding same are provided. Also provided are methods and pharmaceutical compositions which can be used to treat ANP-related diseases and disorders including cardiovascular disorders using the polypeptides and polynucleotides of the present invention. | 2009-02-05 |
20090035288 | EDIBLE PRODUCT CONTAINING BENEFICIAL BACTERIA - The present invention provides a method of preparing an edible product comprising non-viable bacteria providing a health benefit, the method comprising subjecting viable bacteria to at least two sub-lethal treatments to obtain the non-viable bacteria providing a health benefit, each sub-lethal treatment on its own not being sufficient to render the bacteria non-viable. The method porvides non-viable bacteria providing health benefits but which can conveniently be incorporated into a range of edible products. | 2009-02-05 |
20090035289 | DRY PLATELET COMPOSITION - The invention features a dry platelet composition and methods of making and using the freeze-dried platelet composition. | 2009-02-05 |
20090035290 | Glycine N-methyltransferase (GNMT) Animal model and use thereof - The present invention is a new type of Glycine N-methyltransferase (GNMT) knockout mice model. This model can be applied to screen drug, test of treatment and search for diagnostic marker of hepatocellular carcinoma (HCC), glycogen storage disease, liver dysplasia, fatty liver and other liver disease. | 2009-02-05 |
20090035291 | THERAPEUTIC USE OF ADPASE ENHANCED APYRASES - The present invention provides for design and therapeutic use of ADPase enhanced polypeptides, pharmaceutical compositions, and methods useful for preventing and reversing platelet aggregation and recruitment for the treatment and prevention of vascular disorders in mammals. | 2009-02-05 |
20090035292 | Use of phosphatases to treat neuroblastomas and medulloblastomas - Disclosed herein are methods of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a phosphatase ligand in an amount effective to treat the subject. Also disclosed herein are method of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a histone deacteylase ligand in an amount effective to treat the subject. | 2009-02-05 |
20090035293 | Amylases for Pharmaceutical Use - The pharmaceutical use of amylases related to | 2009-02-05 |
20090035294 | LIPOPOLYSACCHARIDE FRACTIONS OF VITREOSCILLA FILIFORMIS USEFUL FOR STIMULATING THE SYNTHESIS OF ANTI-MICROBIAL PEPTIDES OF THE SKIN - Specific fractions of | 2009-02-05 |
20090035295 | Screening Method, Process for Purifying of Non-Diffusible A-Beta Oligomers, Selective Antibodies Against Said Non-Diffusible a-Beta Oligomers and a Process for Manufacturing of Said Antibodies - The present invention is relates to non-diffusible globular Aβ(X-38 . . . 43) oligomers (“globulomers”) or derivatives thereof, methods for enriching said globulomers or derivatives, compositions comprising said globulomers or derivatives, antibodies and aptamers having specificity for said globulomers or derivatives, methods for preparing such antibodies and aptamers, uses of said globulomers or derivatives, or of said antibodies or aptamers for diagnostic, therapeutic and other purposes, and corresponding methods using said globulomers or derivatives, or said antibodies or aptamers. | 2009-02-05 |
20090035296 | COMPOUNDS AND METHODS FOR TREATMENT AND DIAGNOSIS OF CHLAMYDIAL INFECTION - Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a | 2009-02-05 |
20090035297 | Methods for treating diabetes - Methods for treating diabetes by administering an inhibitor of GDF-8, or a related member of Transforming Growth Factor-beta (TGF-β) superfamily of structurally-related growth factors (e.g., GDF-11) are disclosed. Also disclosed are methods for upregulating expression of hexose transporters, such as GLUT4 and GLUT1, in a subject by administering an inhibitor of GDF-8. Also disclosed are methods for increasing glucose uptake by cells in a subject, by administering an inhibitor of GDF-8. | 2009-02-05 |
20090035298 | METHODS TO TREAT ALZHEIMER'S DISEASE OR OTHER AMYLOID BETA ACCUMULATION ASSOCIATED DISORDERS - The present invention provides methods for treating amyloid-beta accumulation-associated disorders, such as Alzheimer's disease. The methods comprise modulating the concentration of amyloid-beta in the brain interstitial fluid. In particular, the methods comprise modulating the activity of corticotrophin-releasing factor (CRF), which in turn modulates the concentration of amyloid-beta. | 2009-02-05 |
20090035299 | Methods and compositions for treating diseases targeting MABA1 - Methods and compositions for diagnosing, detecting and treating a colon disease associated with differential expression of MABA1 in comparison to healthy cells. Also provided are antagonists or agonists of MABA1, and methods for screening agents that modulate the MABA1 level or activity in vivo or in vitro. | 2009-02-05 |
20090035300 | IMMUNOMODULATION OF DENDRITIC CELLS - The present invention relates to isolated nucleic acid molecule encoding the transcription regulator DC-SCRIPT or a derivative thereof. The invention further relates to its use in therapy and to compound for interfering with the biological function of the transcription factor DC-SCRIPT. Such compounds can be compounds interfering with expression of DC-SCRIPT; or compounds interfering with binding of DC-SCRIPT to DNA. | 2009-02-05 |
20090035301 | METHODS FOR DIAGNOSING AND TREATING BLADDER CANCER - The present invention relates to the diagnosis and treatment of bladder cancer. More specifically, this invention uses the levels of macrophage migration inhibitory factor (MIF) produced by the bladder epithelia (urothelia) as a marker for bladder cancer. Moreover, the present invention also provides a method for attenuating bladder carcinoma by inhibiting of macrophage MIF. | 2009-02-05 |
20090035302 | Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith - Disclosed are RAGE antagonist compounds that have the ability to reverse pre-existing amyloidosis. Treatment with the RAGE antagonist compounds described herein may be used to reduce plaque size and improve cognition for subjects in the later stages of Alzheimer's disease. Additionally, the RAGE antagonists described herein may be used to reduce the onset of plaque formation and thereby prevent loss of cognition and other symptoms associated with Alzheimer's Disease and other diseases of amyloid deposition. | 2009-02-05 |
20090035303 | METHODS OF DETECTING METHYL TRANSFERASE ACTIVITY AND METHODS OF SCREENING FOR METHYL TRANSFERASE ACTIVITY MODULATORS - The invention features a method for determining methyl transferase activity of a polypeptide and screening for modulators of methyl transferase activity. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer or hepatocellular carcinoma using the modulator. | 2009-02-05 |
20090035304 | Use of Tgf-beta Antagonists to Limit Nephrotoxicity of Immunosuppressive Agents - The disclosure relates to methods of ameliorating nephrotoxic side effects of immunosuppressive agents whose immunosuppressive activity is mediated via upregulation of TGF-β such as, for example, cyclosporine (CsA). The disclosure provides treatment modalities for use in patients that require immunosuppression, e.g., patients at risk of transplant rejection or having an autoimmune disease. In the methods of the invention, a TGF-β antagonist, e.g., an anti-TGF-β antibody, is administered to a patient treated with an immunosuppressive agent. Such a TGF-β antagonist is administered in a therapeutically effective amount sufficient to alleviate the nephrotoxic effects of the immunosuppressive agent without substantially interfering with immunosuppressive activity of the agent. | 2009-02-05 |
20090035305 | Compositions and Methods for Treating Viral Infection - Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus. | 2009-02-05 |
20090035306 | QUINAZOLINONE MODULATORS OF TGR5 - The present invention relates to quinazolinone compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases. | 2009-02-05 |
20090035307 | Abeta CONFORMER SELECTIVE ANTI-Abeta GLOBULOMER MONOCLONAL ANTIBODIES - The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto. | 2009-02-05 |
20090035308 | Methods for using and identifying modulators of Delta-like 4 - In certain embodiments, this present invention provides methods of identifying and using agonists and antagonists of Delta-like 4 (Dll4) signaling. | 2009-02-05 |
20090035309 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase - New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer. | 2009-02-05 |
20090035310 | CANCER TREATMENT - Pharmaceutical compositions and methods for inhibiting tumor growth and/or for inducing apoptosis are provided. Such compositions comprise at least one polypeptide of contiguous amino acids 1-198, 197-454, or 896-1150 of CARP-1 protein, and derivatives thereof, and may optionally comprise one or more cancer chemotherapeutic agents. Also provided are plasmids encoding the polypeptides, and methods of using the polypeptides and plasmids to inhibit cancer cell growth, including in mammals. | 2009-02-05 |
20090035311 | Identification and use of prognostic and predictive markers in cancer treatment - The present invention provides a method of screening for markers useful in predicting the efficacy of the treatment of a specified cancer that includes: (a) constructing a tissue microarray from a tissue bank comprising multiple tissue samples that are annotated with clinical follow-up data; (b) labeling polynucleic acid probes specific for oncogenes or cancer-associated genes known to be potential amplicons; (c) performing fluorescent in situ hybridization analysis on the tissue microarray; and (d) correlating the result of the fluorescent in situ hybridization with the clinical follow-up data. In addition, the present invention provides a method of treating breast cancer that includes measuring the expression levels or amplification of HTPAP in a patient having breast cancer and then providing a patient having increased levels of HTPAP expression or HTPAP amplification with therapeutic quantities of at least one compound that interferes with the phosphatidic acid phosphatase activity of HTPAP. The present invention also encompasses a method of treating breast cancer that includes screening a breast cancer patient for amplification of the cMYC gene and then treating a patient having amplification of the cMYC gene with therapeutic quantities of a compound that interferes with HER | 2009-02-05 |
20090035312 | TUMOR ANGIOGENESIS ASSOCIATED GENES AND A METHOD FOR THEIR IDENTIFICATION - Methods of identifying specific target molecules for design of anti-angiogenic and vascular targeting approaches are disclosed. Transcriptional profiles of tumor endothelial cells were compared with that of normal resting endothelial cells, normal but angiogenically activated placental endothelial cells, and cultured endothelial cells. Although the majority of transcripts were classified as general angiogenesis markers, 17 genes were identified that show specific overexpression in tumor endothelium. Antibody targeting of four cell-surface expressed or secreted products (vimentin, CD59, HMGB1 and IGFBP7) inhibited angiogenesis in vitro and in vivo. Finally, targeting endothelial vimentin in a mouse tumor model significantly inhibited tumor growth and reduced microvessel density. The results demonstrate the utility of the identification and subsequent targeting of specific tumor endothelial markers for anticancer therapy. | 2009-02-05 |
20090035313 | Compounds - This invention relates to nicotinamide derivatives of general formula (I): | 2009-02-05 |
20090035314 | Method and pharmaceutical composition for preventing or treating diseases associated with inflammation - The present invention relates to a method and pharmaceutical composition for preventing or treating inflammatory diseases. More particularly, the present invention relates to a method for inhibiting lymphocyte adhesion to an endothelial cell, or a method for treating an inflammatory disease, which comprises administering to a subject in need thereof an inhibitor against lymphocyte adhesion to a FEX-2 polypeptide. A pharmaceutical composition comprising the inhibitor against lymphocyte adhesion to a FEX-2 polypeptide, and the use of the inhibitor against lymphocyte adhesion to a FEX-2 polypeptide are also disclosed. Further, a method for screening a medicament for inhibiting lymphocyte adhesion to a FEX-2 polypeptide or a medicament for treating an inflammatory disease, which comprises a step of selecting an inhibitor against lymphocyte adhesion to a FEX-2 polypeptide, is disclosed. | 2009-02-05 |
20090035315 | Method of Improving Treatments in Rheumatic and Arthritic Diseases - Improved treatments of joint diseases, such as, e.g. osteoarthritis and rheumatoid arthritis, and pain, wherein a strontium-containing compound is administered alone or in combination with one or more second therapeutically and/or prophylactically active substances, selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compounds (DMARDs), selective estrogen receptor modulators (SERMs), aromatase inhibitors, non-steroidal anti-inflammatory agents (NSAIDs), COX-2 inhibitors, COX-3 inhibitors, opioids, inhibitors/antagonists of IL-1, inhibitors/antagonists of TNF-alpha, inhibitors of matrix metallo-proteinases (MMPs), cathepsin K inhibitors, inhibitors/antagonists of RANK-ligand, statins, glucocorticoids, chondroitin sulphate, NMDA receptor antagonists, inhibitors of interleukin-I converting enzyme, Calcitonin gene related peptide antagonists, glycine antagonists, vanilloid receptor antagonists, inhibitors of inducible nitric oxide synthetase (iNOS), N-acetylcholine receptor agonists, neurokinin antagonists, neuroleptic agents, PAR2 receptor antagonists and anabolic growth factors acting on joint tissue components. Pharmaceutical compositions comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance as defined above. | 2009-02-05 |
20090035316 | Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer (SCLC) - The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease and of patients having SCLC disease. The antibody-recognized SCLC-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing SCLC cells. | 2009-02-05 |
20090035317 | Peptides binding to vascular endothelial growth factor - The invention relates to peptides that bind to vascular endothelial growth factor (VEGF). The invention further relates to methods of screening for VEGF-binding peptides, methods of using VEGF-binding peptides to detect the presence of VEGF in a biological sample, and methods of using VEGF-binding peptides to modulate VEGF activity and angiogenesis, and as components in a therapeutic or prophylactic composition. | 2009-02-05 |
20090035318 | METHOD AND COMPOSITION FOR INCREASING THE ENGRAFTMENT EFFICIENCY OF STEM CELLS - A method is described for increasing the engraftment efficiency of S/G | 2009-02-05 |
20090035319 | Antibodies Against C3a Receptor - The present invention relates to antibodies and related molecules that specifically bind to C3a Receptor. Such antibodies have uses, for example, in the prevention and treatment of asthma, allergy, and other related inflammatory and immune disorders. The invention also relates to nucleic acid molecules encoding anti-C3a Receptor antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially inflammatory and other related disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to C3a Receptor. | 2009-02-05 |
20090035320 | Agents for Regulating Liver Regeneration/Repair - The present invention relates to uses of PCI, which inhibits HGFa activity, and to uses of anti-PCI antibodies, which neutralize HGFa inhibition; and to agents for regulating and controlling tissue regeneration and/or repair, with PCI as an active ingredient; and to agents for enhancing tissue regeneration and/or repair, with anti-PCI antibodies as active ingredients (particularly, anti-PCI antibodies with the action of neutralizing PCI (anti-PCI neutralizing antibodies)). | 2009-02-05 |
20090035321 | Intercellular adhesion molecules and their binding ligands - The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them. | 2009-02-05 |
20090035322 | Human Antibodies to Human CD20 and Method of Using Thereof - A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing symptom free survival time between about 2-fold to about 9-fold or more, relative to control-treated animals in a mouse model of human lymphoma. The antibody or antigen-binding fragment thereof is useful in a therapeutic method for treating a CD20-mediated disease or condition, such as for example, non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, chronic lymphocytic leukemia, and inflammatory diseases. | 2009-02-05 |
20090035323 | IMMUNE RESPONSE MODIFIER CONJUGATES - The present invention provides IRM conjugates that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety in which the covalent link does not depend on UV irradiation. | 2009-02-05 |
20090035324 | NOVEL PYRIMIDINECARBOXAMIDE DERIVATIVES - This disclosure relates to novel HIV integrase inhibitors their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating HIV infections. | 2009-02-05 |
20090035325 | CANINE INFLUENZA VIRUS AND RELATED COMPOSITIONS AND METHODS OF USE - The present invention provides an isolated canine influenza virus of subtype H3N8 comprising an HA having SEQ ID NO: 4 or an amino acid sequence that is greater than 99% identical to SEQ ID NO: 4, with the proviso that the amino acids at positions 94 and 233 are identical to SEQ ID NO: 4; a composition comprising attenuated or inactivated virus; isolated or purified HA, NM, NP, M1, NS1, PA, PB1, and PB2 proteins and fragments thereof and compositions comprising same or nucleic acids, optionally as part of a vector, encoding same; and a method of inducing an immune response to canine influenza virus in an animal comprising administering to the animal an aforementioned composition. | 2009-02-05 |
20090035326 | COMPOSITIONS WITH ANTIGENS ADSORBED TO CALCIUM PHOSPHATE - Calcium phosphate is used as an adjuvant, with a high degree of antigen adsorption to the adjuvant. The invention is particularly useful for adjuvanting conjugated capsular saccharide antigens. Buffers, such as phosphate or histidine buffers, can advantageously be used in combination with the calcium phosphate, and compositions may have a pH in the range of 5.5 to 7.5. | 2009-02-05 |
20090035327 | Antibody Gene Transfer and Recombinant AAV Therefor - The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified. | 2009-02-05 |
20090035328 | fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS - The present invention generally provides methods and compositions for eliciting an immune response against | 2009-02-05 |
20090035329 | DIAGNOSTIC AND TREATMENT METHODS FOR CHARACTERIZING BACTERIAL MICROBIOTA IN SKIN CONDITIONS - The present invention relates to methods for characterization of bacterial skin microbiota to provide diagnostic, therapeutic, and preventive measures for alleviating skin conditions. In certain embodiments, the invention relates to characterization of bacterial skin microbiota associated with psoriasis and related diagnostic, therapeutic, and preventive measures for alleviating psoriasis. These methods will be useful for detecting, diagnosing, and monitoring individuals who have or are at risk of certain skin conditions. | 2009-02-05 |
20090035330 | Vaccine Composition Comprising B-Subunit Of E. coli Heat Toxin And An Antigen And An Adjuvant - The present invention provides a vaccine composition comprising the B-subunit of | 2009-02-05 |
20090035331 | Systems and Methods for Targeted and Controlled Delivery of Agents - An Agent Delivery System allows for targeted and controlled delivery of an agent or agents to target site, such as specific cells or a specific tissue of an individual. An exemplary Agent Delivery System includes a platform, having a silica crystal lattice base plate, coated with a collagen-containing layer. At least one agent of interest is disposed within the platform, for delivering to the target site. The agent is released when the Agent Delivery Platform is exposed to collagen-degrading compounds. Collagen-degrading compounds can be secreted by cells within a target site. | 2009-02-05 |
20090035332 | PHARMACEUTICAL FORMULATION - This invention relates to a stable pharmaceutical formulation containing olanzapine. The composition comprises olanzapine or a pharmaceutically acceptable salt thereof, and one or more suitable pharmaceutical excipients, wherein the composition is coated with a coating comprising polyvinyl alcohol. | 2009-02-05 |
20090035333 | COSMETIC SKIN PREPARATION - A cosmetic skin preparation containing a porous powder which contains water absorbed therein and whose surface is coated with a binder containing a crosslinked type organopolysiloxane. | 2009-02-05 |
20090035334 | METHOD FOR PREPARING POLYMETHYLMETHACRYLATE SPHERICAL BEAD - This invention provides a method for preparing a polymethylmethacrylate spherical bead and in particular, it provides a method for preparing a polymethylmethacrylate spherical bead characterized in that it is prepared by preparing polymethylmethacrylate by polymerizing methyl-methacrylate monomers, evaporating remaining methylmethacrylate monomers by raising temperature up to at least 100° C. after the polymerization reaction, and washing the polymethylmethacrylate with a mixed solvent of ethanol and water and vacuum drying them. The polymethylmethacrylate spherical beads in accordance with the invention not only can provide pure polymethylmethacrylate in its odorless condition by completely eliminating the remaining methylmethacrylate monomers that generate off-odor but also show no yellowing and at the same time, they are suitable for cosmetic materials or industrial materials because they are harmless to human and have no off-odor | 2009-02-05 |
20090035335 | Cosmetic Composition Containing a Polymer Blend - The present invention relates to a cosmetic composition containing a unique polymer blend, which includes: (a) a first polymeric film-former having a first glass transition temperature ranging from about −20° C. to about 0° C.; (b) a second polymeric film-former having a second glass transition temperature that is at least 50° C. higher than the first glass transition temperature; and (c) a third cross-linked polymeric film-former. The cosmetic composition of the present invention can be applied to human skin or keratinous fibers for forming a film thereon with exceptionally long wearability, reduced flaking and smudge properties, and good removability by warm water. | 2009-02-05 |
20090035336 | ISOFLAVONE NANOPARTICLES AND USE THEREOF - The present invention is directed to isoflavone nanoparticle compositions comprising isoflavone in the form of nanoparticles and preferably a carrier. The isoflavone nanoparticle compositions are particularly useful for preparing cosmetic compositions, pharmaceutical compositions, foodstuff, food and feed additives. In the compositions comprising the isoflavone nanoparticle compositions recrystallization of the isoflavone to bigger particles is retarded. | 2009-02-05 |
20090035337 | Fluid Reservoir - Fluid reservoirs which are based on polymer substrates and are capable of storing large amounts of fluids. The storage is reliable and the reemergence from the liquid reservoir is readily controllable, for example, via the temperature or via mechanical actions, to achieve retardation of the fluid release. Also, processes for producing such fluid reservoirs and also their use, for example in washing or cleaning compositions. | 2009-02-05 |
20090035338 | Inverse emulsions comprising avermectins and cosmetic/dermatological applications thereof - Physically and chemically stable, oxidation-resistant, cosmetic/dermatological inverse emulsions contain a therapeutically effective amount of at least one avermectin compound, notably ivermectin, a glycolic or aqueous/glycolic dispersed hydrophilic phase, a continuous lipophilic phase and an emulsifier having an HLB ranging from 2 and 7, and are useful for the treatment of a variety of dermatological conditions/afflictions, e.g., rosacea. | 2009-02-05 |
20090035339 | Methods of Inactivating Viruses - A method of inactivating viruses is provided. The method comprises the step of topically applying an antimicrobial composition comprising: an organic acid; and an anionic surfactant mixture having a characteristic selected from the group consisting of: a linear alkyl chain having a chain length of from about C | 2009-02-05 |
20090035340 | PRESERVATIVE COMPOSITIONS FOR MOIST WIPES - The present disclosure generally relates to a composition for use with personal care products. The composition comprises a preservative system comprising methylisothiazolinone and a benzoic acid salt or derivative thereof. The weight ratio of methylisothiazolinone and benzoic acid salt in the composition is from about 1:30 to about 1:100. Also disclosed are personal care products, such as wet wipes, impregnated with the composition. | 2009-02-05 |
20090035341 | COATING MATERIAL - The invention relates to an antimicrobial and preferably non-cytotoxic coating material and to use of said coating material. | 2009-02-05 |
20090035342 | Antimicrobial Devices and Compositions - The present invention comprises methods and compositions for antimicrobial devices comprising metal containing compositions which are resistant to heat and light discoloration. The metal containing compositions may comprise salts or complexes of silver, copper or zinc. In one aspect the compositions comprise silver salts. In another aspect, the compositions comprise silver complexes. In one aspect, the metal salts may comprise metal salts of saccharin, acesulfame, long chain fatty acids, and alkyl dicarboxylic acids. The compositions further comprise polymers which form salts or complexes with silver, copper or zinc. The methods of the present invention comprise treating devices with the metal containing compositions, including, but not limited to, such devices as woven wound care materials, catheters, patient care devices, and collagen matrices. The present invention further comprises treatment of humans and animals with the antimicrobial devices described herein. | 2009-02-05 |
20090035343 | DELIVERY OF DRY FORMULATIONS OF OCTREOTIDE - Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent. | 2009-02-05 |
20090035344 | MULTI-POLYMER HYDROGELS - The invention provides a multi-polymer hydrogel article having a first polymeric, water-swellable material and a second polymeric material, organized such that a first region substantially comprises the first polymeric, water-swellable material, a second region adjacent the first region comprises a mixture of the first polymeric, water-swellable material and the second polymeric material, and a third region adjacent the second region substantially comprises the second polymeric material. The article exhibits an increasing concentration gradient of the second polymeric material moving from the first region, through the second region, to the third region. The invention also provides methods for forming a multi-polymer hydrogel article by (a) forming a hydrogel structure using a first polymeric, water-swellable material, (b) creating an aerogel structure having a plurality of open pores by dehydrating the hydrogel structure, (c) contacting the aerogel structure with a second polymeric material to incorporate the second polymeric material into at least a portion of the plurality of open pores to form the multi-polymer hydrogel article, and (d) rehydrating the multi-polymer hydrogel article. | 2009-02-05 |
20090035345 | Nuclear Receptors Agonists for Treatment of Atherosclerosis and/or Related Cardiovascular Disease - The invention relates to the use of an agonist of one or more of the nuclear receptors TR3, MINOR and NOT for the preparation of a medicament for the treatment of cardiovascular disease, in particular in-stent restenosis and/or vein-graft disease. The invention further relates to medical devices, such as stents and cuffs, that are coated with the agonist, or in which the agonist is incorporated and which are for use in the treatment of in-stent restenosis or vein-graft disease. | 2009-02-05 |
20090035346 | Methods and Compositions for Enhancing Vascular Access - Disclosed is an implantable material comprising a biocompatible matrix and cells which, when provided to a vascular access structure, can promote functionality generally. For example, implantable material of the present invention can enhance maturation of an arteriovenous native fistula as well as prolong the fistula in a mature, functional state suitable for dialysis. Additionally, the present invention can promote formation of a functional arteriovenous graft suitable for dialysis as well as promote formation of a functional peripheral bypass graft. Implantable material can be configured as a flexible planar form or a flowable composition with shape-retaining properties suitable for implantation at, adjacent or in the vicinity of an anastomoses or arteriovenous graft. According to the methods disclosed herein, the implantable material is provided to an exterior surface of a blood vessel. Certain embodiments of the flexible planar form define a slot. The materials and methods of the present invention comprise cells, preferably endothelial cells or cells having an endothelial-like phenotype. | 2009-02-05 |
20090035347 | ISOLATED STROMAL CELLS AND METHODS OF USING THE SAME - Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed. The methods comprise introducing into such individuals, stromal cells that are administered in a manner that physically isolates them from the recipient's immune system and that comprise a gene construct that comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. | 2009-02-05 |
20090035348 | DISSOLUTION OF ARTERIAL PLAQUE - Some embodiments of the present invention provide pharmaceutical formulations, for treating atherosclerosis in a mammal, including a bile acid and/or a terpene atherosclerotic plaque emulsifier. Some embodiments provide methods for administering such pharmaceutical formulations. In some embodiments, pharmaceutical formulations include a combination of a bile acid and a terpene in amounts effective to result in plaque regression, and the amount of each individual emulsifier in the combination can be lower than an amount that is effective to result in plaque regression when the emulsifier is administered alone. In some embodiments, a statin can be administered simultaneously or sequentially with the pharmaceutical formulation. | 2009-02-05 |
20090035349 | Composite scaffolds and methods using same for generating complex tissue grafts - A composite scaffold for engineering a heterogeneous tissue is provided. The composite scaffold includes: (a) a first scaffold being capable of supporting formation of a first tissue type thereupon; and (b) a second scaffold being capable of supporting formation of a second tissue type thereupon; wherein the first scaffold and the second scaffold are arranged with respect to each other such that when the first scaffold supports the first tissue type and the second scaffold supports the second tissue type, a distance between any cell of the second tissue type and the first tissue type does not exceed 200 μm. | 2009-02-05 |
20090035350 | Polymers for implantable devices exhibiting shape-memory effects - The present invention is directed to polymeric compositions comprising a biodegradable copolymer that possesses shape-memory properties and implantable devices (e.g., drug-delivery stents) formed of materials (e.g., a coating) containing such compositions. The polymeric compositions can also contain at least one non-fouling moiety, at least additional biocompatible polymer, at least one biobeneficial material, at least one bioactive agent, or a combination thereof. The polymeric compositions are formulated to possess good mechanical, physical and biological properties. Moreover, implantable devices formed of materials comprising such compositions can be delivered to the treatment site in a conveniently compressed size and then can expand to dimensions appropriate for their medical functions. | 2009-02-05 |
20090035351 | Bioabsorbable Hypotubes for Intravascular Drug Delivery - A biodegradable implantable device for delivering a drug to a treatment site includes a biodegradable hypotube defining a lumen and at least one drug disposed within the lumen of the hypotube. At least one drug is released from the lumen upon degradation of the biodegradable hypotube. The lumen may be compartmentalized, each compartment containing a different drug. The hypotube may also include a plurality of pores in fluid communication with the compartments providing different drug release profiles. | 2009-02-05 |
20090035352 | Drug Delivery Particle - A drug delivery particle including a reservoir region having primarily large pores and a metering region. The particle can be highly spherical. | 2009-02-05 |
20090035353 | NON-ABSORBENT ARTICLES CONTAINING ADDITIVES - Non-absorbent articles containing an additive are disclosed. The non-absorbent articles include an effective amount of an inhibitory compound such as cerulenin, triclosan, or hexachloroprene, for example, to substantially inhibit the production of TSST-1 by Gram positive bacteria. | 2009-02-05 |
20090035354 | Device and Method for Treating the Anal Sphincter - A rectally insertable device for localized drug delivery to the anal sphincter of a subject, a method of using the device and the use of the device is disclosed. The device comprises a shell for containing an active pharmaceutical ingredient, the shell being substantially impermeable to the active pharmaceutical ingredient wherein a lower portion of the shell is configured to release the active pharmaceutical ingredient from the shell and wherein when the device is inserted into the rectum of the subject, the lower portion of the shell is proximal to the anal sphincter, such that the active pharmaceutical ingredient is released proximal to the anal sphincter. | 2009-02-05 |
20090035355 | CONFECTIONERY PRODUCTS AND PROCESS FOR OBTAINING THEM - Agglomerates comprising calcium-hydrocolloid-composite materials and at least one sugar alcohol, as well of methods for preparing the agglomerates and various applications thereof. | 2009-02-05 |
20090035356 | MODIFIED BIODEGRADABLE POLYMERS, PREPARATION AND USE THEREOF FOR MAKING BIOMATERIALS AND DRESSINGS - The invention concerns a method for preparing a modified biodegradable polymer in aqueous medium comprising at least two steps. The first step is a reaction between an amino acid, a peptide or a polypeptide and maleic anhydride to form a compound having an unsaturated vinyl-carboxylic acid function. In the second reaction step, the unsaturated diacid obtained in the first step is reacted with a biodegradable polymer having at least one primary amine function, such as a fibrous protein or a glycosaminoglycan. The preferred polymer used is collagen or chitosan. The invention also concerns the modified biodegradable polymer obtained by the method. The invention further concerns a biomaterial or a dressing containing the modified biodegradable polymer having biocompatible, cytocompatible, hemostatic, bactericidal and wound healing properties, and its medical, biomedical, pharmaceutical or cosmetic use. | 2009-02-05 |
20090035357 | Method of drug delivery using a transdermal device having a phase change material - A method of drug delivery utilizes a transdermal device that contains a phase change material and a first material such as a drug, a pharmaceutical, or a medicament mixed with or disposed near the phase change material. The phase change material is one that transitions from solid to liquid form when heated. A second material is disposed, suspended, or held in the solid form of the phase change material. The phase change material changes to a liquid state in response to heat and the second material that is disposed, suspended, or held in the phase change material is released and comes into contact with the first material. Advantageously, such second materials may include substances such as pharmaceuticals that boost or supplement the effect produced by a drug delivered transdermally by the device, or drug antagonists, or nicotine. | 2009-02-05 |
20090035358 | PHOSPHATIDYL OLIGOGLYCEROLS - In order to form liposomes with a longer half-life in blood, use is made of defined compounds with the general formula (A) | 2009-02-05 |
20090035359 | IMMUNOGENIC FRAGMENTS OF T-CELL RECEPTOR CONSTANT DOMAINS AND PEPTIDES DERIVED THEREFROM - The present invention is directed to an isolated T-Cell Receptor constant domain and to peptides derived therefrom and recombinant constructs encoding same, effective in therapy of T cell mediated inflammatory disease, autoimmunity and graft rejection. Therapeutic and prophylactic vaccine compositions and methods utilizing these proteins and peptides, DNA vaccines encoding same and T cell vaccines thereof are further provided. | 2009-02-05 |
20090035360 | LYOPHILISED ANTIGEN COMPOSITION - The present invention provides lyophilised compositions comprising an antigen and a Toll-like receptor (TLR) 9 agonist. Such compositions may be reconstituted into immunogenic compositions for use in vaccination with a carrier selected from the group of particulate carriers consisting of liposomes, mineral salts, emulsions, polymers and ISCOMs. Methods of making immunogenic compositions from the lyophilised compositions of the invention and use of the same in immunisation are also herein provided. | 2009-02-05 |
20090035361 | Composition for vaginal use - Compositions for vaginal use comprising lupulus ( | 2009-02-05 |
20090035362 | Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss - The present invention includes methods and compositions useful for treating and preventing skin disorders, hair loss and other skin disorders. The compositions include an ARD enhancer in combination with a second compound or composition. In some embodiments the second compound is at least one of a bactericide, an antibiotic, an anti-microbial peptide, Vitamin A, a Vitamin A derivative, a retinoid, an anti-inflammatory compound, and anti-androgen compounds. | 2009-02-05 |
20090035363 | Photoactive Compounds and Compositions and Uses Thereof - Photoactive compounds and compositions, as well as methods of using the same. For example, compositions of the invention may be used in Type 1 phototherapy, Type 2 phototherapy, or a combination of Types 1 and 2 phototherapy. | 2009-02-05 |
20090035364 | PARA-SUBSTITUTED 2-ALKOXYPHENOL COMPOUNDS - Para-substituted 2-alkoxyphenols having cooling properties of formula (I) wherein R | 2009-02-05 |
20090035365 | Density Controlled Capsule Particles and Methods of Making the Same - The present invention discloses density controlled capsule particle and methods for making the same for use in a wide range of consumer and personal care products. | 2009-02-05 |